Tagged with J

Global As our thoughts here at PharmaBoardroom turn towards the summer holidays, we are happy to share the five most-read articles from our global contributor network so far in 2021. These thought leadership pieces cover topics as vital and diverse as the latest regulatory updates from China; EU-UK pharma trade; the…

Singapore Singapore is one of the healthiest countries in Asia with a life expectancy in excess of 82 years buttressed by one of the most robust healthcare apparatuses in the world. “It’s important not to overlook the strengths of this system and just how strong healthcare delivery, affordability and access is…

Japan Writing in the July issue of DIA’s Global Forum magazine Pfizer R&D Japan’s Atsushi Kitamura examines how both pharmaceutical companies and patients in Japan can help increase patient engagement in the clinical trial process.   Patient engagement in clinical trials in Japan has been progressing steadily in the last few…

South Africa With Africa struggling to vaccinate its populations against COVID-19, the World Bank – along with government institutions from the USA, Germany, and France – has intervened to loan South African firm Aspen Pharmacare EUR 600 million (USD 712 million) with the aim of increasing vaccine manufacturing know how across the…

Japan While the overall Japanese pharma market is expected to remain at a similar overall value up to 2023, the oncology segment is expected to grow by five percent and by 2026, oncology is expected to represent one-fifth of the entire market. Cancer is one of the top three leading causes…

Turkey After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and is aiming to give back to her country by improving patients’ access to life-saving therapies.   For Russ, what began as a consultant role at McKinsey…

Turkey Janssen’s Managing Director for Turkey, Demet Russ, discusses her return to the country after 25 years abroad, having worked for Johnson & Johnson in different local, regional and global roles in Germany, Belgium, France and the US. She explains how Janssen Turkey’s vision “We are here for the better” is…

Japan Writing in the June edition of DIA’s Global Forum magazine, representatives of Japanese pharmaceutical companies with US operations outline how the COVID-19 pandemic affected their ongoing clinical studies.   The spread of COVID-19 and the resulting social activity restrictions have severely impacted drug development and threatened the continuity of clinical…

Switzerland Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide, forming collaborations between entrepreneurs and the Johnson & Johnson Family of Companies’ global healthcare businesses. Michael Hübner, Early Innovation Partnering Lead and member of the Swiss Johnson & Johnson Leadership Team discusses how they support breakthrough early innovation…

Germany The latest news from German pharma, including a new US leadership team and more COVID-related investment at Merck KGaA; the CureVac vaccine’s role in fighting COVID-19 variants; and why the country is trailing its European neighbours in digital health.   Merck KGaA’s new CEO shakes up U.S. leadership to spark…

Japan “This marks a significant moment in Takeda’s history and is an exciting step forward as we accelerate our transformation journey,” said Christophe Weber, Takeda’s CEO, after the USD 62 billion acquisition of international biotech Shire was completed in 2019. Two years later, the Japanese giant appears to finally be on…

Japan Toshio Fujimoto, MD, MBA, the General Manager of Shonan Health Innovation Park examines why Japan – despite being well established as one of the world’s most innovative and technologically advanced countries – has lagged behind in terms of VC funding, especially in the life sciences and how this can be…